Briefing from Abbott on groundbreaking artificial heart program in Libya

AmCham was pleased to organize a briefing from AmCham Member Abbott on its groundbreaking artificial heart program in Libya. Abbott, a leading U.S. healthcare company, was pleased to share with AmCham members the recent implementation of its LVAD artificial heart program in Libya. Designed for patients with advanced heart failure, this type of technology was previously not available in Libya, resulting in either expensive and complicated treatment outside of Libya, or the death of the patient. Abbott invested in the training of a team of surgeons from Tripoli and Benghazi, and these teams are now able to perform this life-saving treatment in Libya. This results in significant financial savings, capacity building for Libyan doctors, and, most importantly, saving Libyan lives.

AmCham was honored by the opportunity to arrange this important meeting.